# A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

> **NCT06926283** · PHASE1 · RECRUITING · sponsor: **Hangzhou DAC Biotechnology Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Prostate Cancer
- Other Solid Tumors
- Ewing Sarcoma

## Interventions

- **DRUG:** DXC008

## Key facts

- **NCT ID:** NCT06926283
- **Lead sponsor:** Hangzhou DAC Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926283, "A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06926283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*